Esperion Therapeutics, Inc. (ESPR)
3.43
+0.03
(+0.88%)
USD |
NASDAQ |
Feb 13, 16:00
3.435
0.00 (0.00%)
After-Hours: 20:00
Esperion Therapeutics EPS Diluted (Quarterly) : -0.1561 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Nektar Therapeutics | -1.875 |
| Rigel Pharmaceuticals, Inc. | 1.456 |
| AnaptysBio, Inc. | 0.5208 |
| ACADIA Pharmaceuticals, Inc. | 0.4206 |
| Alnylam Pharmaceuticals, Inc. | 1.368 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -31.33M |
| Revenue (Quarterly) | 87.31M |
| Total Expenses (Quarterly) | 118.64M |
| Enterprise Value | 1.329B |
| Gross Profit Margin (Quarterly) | 52.71% |
| Profit Margin (Quarterly) | -35.89% |
| Earnings Yield | -15.62% |
| Normalized Earnings Yield | -15.45 |